In addition, a comprehensive meta-analysis of SGLT-2 inhibitors indicated a lower risk of cardiovascular mortality (HR 0.85, 95% CI 0.78–0.93), heart failure hospitalization (HR 0.68, 95% CI 0.61–0.76), and major adverse cardiovascular events (HR 90, 95% CI 0.85–0.95) [77]. Here, SLC5A2 is linked to heart failure.